Study estimates new Alzheimer's drug Leqembi could cost Medicare up to $5B per year.
TL;DR Summary
The Alzheimer's antibody treatment Leqembi could cost Medicare up to $5 billion per year, according to a study published in JAMA Internal Medicine. The estimated costs are conservative and could increase depending on demand and other factors. The twice-monthly antibody infusions are priced at $26,500 per year, with additional annual costs estimated at $7,300 per patient. Medicare has severely restricted coverage of the antibody, but has promised to provide broader coverage if the FDA grants full approval of the treatment in July.
- Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates CNBC
- Medicare, FDA urged to press ahead with new Alzheimer's drug Leqembi The Hill
- Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds Reuters
- Alzheimer's drug lecanemab could boost Medicare spending by $5B a year: study FierceHealthcare
- New Alzheimer's Drug Could Cost Medicare $5B a Year Newsmax
Reading Insights
Total Reads
0
Unique Readers
12
Time Saved
2 min
vs 3 min read
Condensed
86%
566 → 82 words
Want the full story? Read the original article
Read on CNBC